drugset / Trial / NCT05248659
Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)
Phase 2/3
Enrolling by invitation
600 enrolled
Otsuka Pharmaceutical Development & Commercialization, Inc.
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the long-term safety and tolerability of sibeprenlimab in subjects with IgAN
Timeline
- Start
- 2022-04-05
- Primary completion
- 2028-12-28
- Completion
- 2029-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sibeprenlimab | Monoclonal antibody | 400 mg | Subcutaneous |